*10010/14/2011 TCOG

*

*

1003110033148

101

*

305530 300504020

*

4(1)1 61 176 61 21 1 362 / 10

*-1

Rating A 10Rating A + Rating B 27Rating D + Rating E010Rating B()5Rating A Rating A + Rating B 11Rating D 3Rating E0 Rating A + Rating B 10Rating D 4Rating E 1

-2B1.22.43.23.3.33.53.6.23.6.33.104.15.1

1.11.21.31.4 2.12.2.12.2.22.32.42.52.6 3.13.23.3.13.3.23.3.33.3.43.43.53.6.13.6.23.7.13.7.23.83.93.6.33.6.43.10 4.14.24.34.44.54.6 5.15.2 6.1

*

*

1.1 Rating E Rating D Rating C50

*

1.1Rating BC Rating AB1.275

*

1.1

*

1.1

*

1.2 1234

*

1.2Rating E Rating D Rating C Rating C

*

1.2Rating BCRating AB

*

1.21-4

*

1.2

*

1.3 Rating E Rating DRating C Rating C

*

1.3Rating BCPDCARating ABPDCA 10097-99

*

1.312

*

1.4 1. 1AJCC 2 32. 4

*

1.4 1. 1AJCC 2 3

*

1.4

*

*

2.1 Rating ERating DRating D Rating C

*

2.1Rating BC Rating AB3000130002

*

2.120

*

2.110097

*

2.2 Rating ERating DRating D95%98% 90%95% Rating C98% 95%98%

*

2.2Rating B98%98%95% Rating A98 96-98

*

2.21.991A/B100%99 A97 B97 + 97 2E+F/D100%99 D97 E9797 F9797

*

2.3 Rating E Rating DRating CRating C Rating BC() Rating AB

*

2.3

*

2.3Rating A 3 1 2 3 3.

*

2.4 Rating E Rating DRating CRating C Rating BC Rating AB

*

2.4

*

2.41. 1234Class1~252.

*

2.5Class1~2 Rating E Rating DRating C Rating C80

*

2.5Rating BC80~95Rating AB95

*

2.5Class1~2Stage

*

2.51. 123 Class1~242.

*

2.51. K/L100 K L2. 10010%Class1-2

*

1962.13Tumor Size96983.4T Clinical T1151172.14Regional Lymph Nodes Examined991003.5N Clinical N1181193.6M Clinical M1201212.15Regional Lymph Nodes Positive1011023.7Clinical Stage Group122124

*

13.10T Pathologic T127129Other Staging System FIGO3.11N Pathologic N130131Other Staging SystemBCLC1013.12M Pathologic M132133Other Staging Systemhistology1013.13Pathologic Stage Group134136

2.42.5

*

2.6class0-3 Rating ERating D Rating C Rating BC Rating AB

*

2.6

*

2.61.1class 0-32class 1-225 class0334(:)56

3.1 Rating ERating DRating CRating CRating BC

3.1Rating AB /

3.11. 1 peer review article 2 3 42. Rating A Hodgkin lymphomaBDiffuse large B cell lymphomaFollicular lymphoma

3.2 Rating ERating DRating CRating C 70 Rating BC 1. 50% 2.

3.2Rating AB 1. 2. class 1~2

3.2

class 1~2 1 2 2

3

1,00061,001-2,00092,00112

3.2

2. 1 2 33. minimum requirement12345comorbidity6 regimensdose

*

3.2

4.CB 5. summary note6. 7.

regimenRTdose

3.3 3.3.1 Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80%

3.3.11 2()TNMAJCC

100

3.3.1

12724 11 [27+1401/ 212] 100 18/2410075 Rating B2.3.2

3.3.2 Rating E20

Rating D20%40%

Rating C40%60%

Rating B60%80%

Rating A80%

3.3.2 1 2 3()

100

3.3.3 Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80% 1. 1 2 3 2. Neoadjuvant

100

3.3.3

94322 211 [34+22+12+01/ 39] 10018/2710067 Rating B2..3.2

3.3.4Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80% curative intent

3.3.4curative intent1 23 1C()

100

3.3.41.

9233 2311 [32+23+13+01/ 39] 10015/2710056 Rating C2. 3.2

3.4 Rating ERating DRating CRating C Rating BC70%

3.4Rating AB

3.4

3.424B 150 2()

1. 2. 3. 4. 5. 6.

7. () 8. 9. 10. 11. 12.

3.5 Rating ERating DRating CRating C 1. 2. 10%

3.5Rating BC 1. 2. 10%5% Rating AB10%20%10%

3.51.2.3. 1. 2.12303

3.5 1 2 312 3 4

3.55.1 conclusion or recommendation2process6.

3.6 3.6.1 Rating E Rating DRating CRating C

3.6.1Rating BC

Rating AB

3.6.1 (Adjuvant)(Neoadjuvant)(Concurrent Chemoradiotherapy , CCRT)

3.6.1 1 peer review article 2 3 4

3.6.2 Rating E Rating DRating CRating C3.6.1Prescription Rating BC Prescription Rating AB

3.6.2 1Prescription

overdose

*

3.6.3 Rating ERating DRating CRating CRating BC Rating AB

*

3.6.3

*

3.6.3

1. (1)(2)(3)ready to use2.

*

3.6.3

*

3.6.3

6.(spill kits)1

Class IIBClass III ()

*

3.6.3

2: () ()( )

Near missnear missing

*

3.6.4 Rating ERating DRating CRating CRating BC Rating AB

*

3.6.41.2. 3. 1.1 2

*

3.6.4

3.6.3

*

3.6.4

1

3.7 3.7.1 Rating ERating DRating CRating C 1. 2.Rating BC Rating AB

3.7.1 1 23. permanent section

3.7.2 Rating ERating DRating CRating C Rating BC

3.7.2Rating AB

3.8 Rating E Rating DRating CRating C Rating BC Rating AB

3.8 CTMRI

3.9 Rating E Rating DRating CRating C() (curative intent)Rating BCRating C (curative intent)

3.9Rating ABRating Ccurative intent 1. 2. 3. 4.

3.91. 1 2CTVPTV2.1peer review article23() 4

3.912CCE

3.10 Rating E Rating DRating CRating C Rating B Rating A

*

3.10 100

()

*

*

4.1123/4 Rating ERating DRating CRating C

*

4.1Rating BCRating AB /

*

4.1Port-AHickmanPICC/

*

4.13.6.4

*

4.2 Rating E Rating DRating CRating C Rating BC Rating AB

*

4.2 3.6.4

*

4.3 Rating E Rating DRating CRating CRating BRating A

*

4.31.3341 3.6.4

*

4.4Rating E Rating DRating CRating C

*

4.4Rating BC 208020 Rating AB 650%

*

4.4()20

*

4.41. 2. 6 6 3. 6

*

4.5 Rating E Rating DRating CRating C50

*

4.5Rating BC Class1~2400 Rating AB

*

4.5 10097

*

4.51122 3 4 3. C

*

4.6 Rating E Rating DRating CRating C Rating BC 1. 2.

*

4.6Rating AB

*

4.6

*

4.6

*

4.6AintakeBMI

*

*

5.1 Rating E Rating DRating CRating C Rating BC Rating AB

*

5.1 2 PDCA

*

5.2 Rating E Rating D Rating C Rating BC Rating AB

*

5.2

*

*

6.1 class1~22,000AIRBclass1~220001A

*

6.1IRB

1. 2.

*